AARD CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Aardvark Therapeutics (NASDAQ: AARD) and notes that a federal class action has been filed. The action covers investors who bought shares in or traceable to Aardvark's February 13, 2025 IPO, as well as securities purchased between February 13, 2025 and May 14, 2026. Investors have until October 13, 2026 to seek appointment as lead plaintiff, creating legal and reputational risk for the company.

Analysis

This is not a fundamental catalyst; it is plaintiff-law-firm marketing around an already-filed case. The relevant market mechanism is incremental governance and disclosure-risk discounting, which can suppress AARD's multiple and reduce strategic-financing flexibility if the company requires additional capital before clinical or commercial milestones. Without verified allegations, damages estimates, insurance coverage, cash balance, or an identified operational disclosure issue, the filing itself does not support a directional fundamental conclusion.

Near term, the October 13 lead-plaintiff deadline is unlikely to be a material standalone trading event. The more consequential 1-3 month catalyst would be a complaint amendment, a company motion-to-dismiss outcome, or any related revision to clinical, regulatory, revenue, or cash-runway guidance; these events can reveal whether litigation is derivative of ordinary post-IPO volatility or reflects a durable information problem. For a development-stage biotech, the 6-18 month risk is indirect: litigation expense and a lower equity valuation can make future dilution more punitive, particularly if cash runway falls below the next major data readout.

Key Decisions for Investors

• No new directional position solely on this notice; treat AARD as an event-risk watch item until the underlying complaint and alleged misstatements are reviewed.
• For existing long exposure, reduce position size or hedge through the next earnings/cash-runway update if AARD lacks at least 12-18 months of cash runway; litigation-driven multiple compression is most damaging when equity issuance is probable.
• Set an alert for a disclosed complaint, motion-to-dismiss ruling, or any guidance/cash-runway revision. A confirmed operational allegation or lowered guidance would justify reassessing AARD downside versus biotech peers, while dismissal or no change in operating disclosures would weaken the litigation overhang thesis.
• Avoid shorting on the press release alone: small-cap biotech borrow costs, limited liquidity, and binary clinical catalysts can dominate a modest legal overhang. Consider a short only if verified disclosures show financing stress or a material trial/regulatory setback.